Cargando…

Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy

Triple-negative breast cancer (TNBC) is usually the most malignant and aggressive mammary epithelial tumor characterized by the lack of expression for estrogen receptors and progesterone receptors, and the absence of epidermal growth factor receptor (HER)2 amplification. Corresponding to 15–20% of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Matou-Nasri, Sabine, Aldawood, Maram, Alanazi, Fatimah, Khan, Abdul Latif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378597/
https://www.ncbi.nlm.nih.gov/pubmed/37510134
http://dx.doi.org/10.3390/diagnostics13142390
_version_ 1785079807342542848
author Matou-Nasri, Sabine
Aldawood, Maram
Alanazi, Fatimah
Khan, Abdul Latif
author_facet Matou-Nasri, Sabine
Aldawood, Maram
Alanazi, Fatimah
Khan, Abdul Latif
author_sort Matou-Nasri, Sabine
collection PubMed
description Triple-negative breast cancer (TNBC) is usually the most malignant and aggressive mammary epithelial tumor characterized by the lack of expression for estrogen receptors and progesterone receptors, and the absence of epidermal growth factor receptor (HER)2 amplification. Corresponding to 15–20% of all breast cancers and well-known by its poor clinical outcome, this negative receptor expression deprives TNBC from targeted therapy and makes its management therapeutically challenging. Type 2 diabetes mellitus (T2DM) is the most common ageing metabolic disorder due to insulin deficiency or resistance resulting in hyperglycemia, hyperinsulinemia, and hyperlipidemia. Due to metabolic and hormonal imbalances, there are many interplays between both chronic disorders leading to increased risk of breast cancer, especially TNBC, diagnosed in T2DM patients. The purpose of this review is to provide up-to-date information related to epidemiology and clinicopathological features, risk factors, diagnosis, biomarkers, and current therapy/clinical trials for TNBC patients with T2DM compared to non-diabetic counterparts. Thus, in-depth investigation of the diabetic complications on TNBC onset, development, and progression and the discovery of biomarkers would improve TNBC management through early diagnosis, tailoring therapy for a better outcome of T2DM patients diagnosed with TNBC.
format Online
Article
Text
id pubmed-10378597
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103785972023-07-29 Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy Matou-Nasri, Sabine Aldawood, Maram Alanazi, Fatimah Khan, Abdul Latif Diagnostics (Basel) Review Triple-negative breast cancer (TNBC) is usually the most malignant and aggressive mammary epithelial tumor characterized by the lack of expression for estrogen receptors and progesterone receptors, and the absence of epidermal growth factor receptor (HER)2 amplification. Corresponding to 15–20% of all breast cancers and well-known by its poor clinical outcome, this negative receptor expression deprives TNBC from targeted therapy and makes its management therapeutically challenging. Type 2 diabetes mellitus (T2DM) is the most common ageing metabolic disorder due to insulin deficiency or resistance resulting in hyperglycemia, hyperinsulinemia, and hyperlipidemia. Due to metabolic and hormonal imbalances, there are many interplays between both chronic disorders leading to increased risk of breast cancer, especially TNBC, diagnosed in T2DM patients. The purpose of this review is to provide up-to-date information related to epidemiology and clinicopathological features, risk factors, diagnosis, biomarkers, and current therapy/clinical trials for TNBC patients with T2DM compared to non-diabetic counterparts. Thus, in-depth investigation of the diabetic complications on TNBC onset, development, and progression and the discovery of biomarkers would improve TNBC management through early diagnosis, tailoring therapy for a better outcome of T2DM patients diagnosed with TNBC. MDPI 2023-07-17 /pmc/articles/PMC10378597/ /pubmed/37510134 http://dx.doi.org/10.3390/diagnostics13142390 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Matou-Nasri, Sabine
Aldawood, Maram
Alanazi, Fatimah
Khan, Abdul Latif
Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy
title Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy
title_full Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy
title_fullStr Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy
title_full_unstemmed Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy
title_short Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy
title_sort updates on triple-negative breast cancer in type 2 diabetes mellitus patients: from risk factors to diagnosis, biomarkers and therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378597/
https://www.ncbi.nlm.nih.gov/pubmed/37510134
http://dx.doi.org/10.3390/diagnostics13142390
work_keys_str_mv AT matounasrisabine updatesontriplenegativebreastcancerintype2diabetesmellituspatientsfromriskfactorstodiagnosisbiomarkersandtherapy
AT aldawoodmaram updatesontriplenegativebreastcancerintype2diabetesmellituspatientsfromriskfactorstodiagnosisbiomarkersandtherapy
AT alanazifatimah updatesontriplenegativebreastcancerintype2diabetesmellituspatientsfromriskfactorstodiagnosisbiomarkersandtherapy
AT khanabdullatif updatesontriplenegativebreastcancerintype2diabetesmellituspatientsfromriskfactorstodiagnosisbiomarkersandtherapy